Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on ARA-290 (Cibinetide) has been registered.
- 3 registered studies in total.
- None are currently enrolling — this research has already happened.
What kind of research
- 3 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 97 people took part in those.
How far along it is
- None have reached phase 3 — the large, late-stage trials where a drug has to prove itself before regulators will approve it.
- None have published results in the medical literature yet, so the findings are not yet open to outside scrutiny.
- The research spans 4 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 3 of 3 trials for ARA-290 (Cibinetide).
The Use of ARA290 for the Treatment of Diabetic Macular Oedema
Belfast Health and Social Care Trust
Diabetic Macular Oedema
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Araim Pharmaceuticals, Inc.
Neuropathy of Sarcoidosis
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
Claes-Göran Östenson
Diabetes Type 2 · Impaired Glucose Tolerance · Impaired Fasting Glucose
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when ARA-290 (Cibinetide) is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.